Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]
The drug dimethyl fumarate used for multiple sclerosis was found by the FTC to be marked up by $3,753 on average in 2022 for a 30-day supply for patients going through insurance
266 , C319C334 (1994)
According to the previous study, the matrix metalloproteinase level was clearly evaluated after ICH, and the activation of MMP9 in astrocytes exacerbated ICH (Lattanzi et al., 2020)
Descriptive analysis of suicidal and self-injurious adverse events among GLP-1RA users The clinical characteristics of GLP-1RA-associated suicide/self-injury are presented in Table 3
Meanwhile, obesity drug biotech Metsera, founded in April 2022, is developing new GLP-1 injectables that can be taken once a month instead of once a week and seem to have fewer side effects than other options